About the Authors
- Laura A. Sullivan
-
Affiliation Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
- Juliet G. Carbon
-
Affiliation Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
- Christina L. Roland
-
Affiliation Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
- Jason E. Toombs
-
Affiliation Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
- Mari Nyquist-Andersen
-
Affiliation Affitech AS, Oslo Research Park, Oslo, Norway
- Anita Kavlie
-
Affiliation Affitech AS, Oslo Research Park, Oslo, Norway
- Kyle Schlunegger
-
Affiliation Peregrine Pharmaceuticals, Inc., Tustin, California, United States of America
- James A. Richardson
-
Affiliation Departments of Pathology and Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
- Rolf A. Brekken
-
* E-mail: rolf.brekken@utsouthwestern.edu
Affiliations Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America, Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
Competing Interests
R. A. Brekken is a consultant for, has equity interest in, and is a recipient of a sponsored research grant from Peregrine Pharmaceuticals and Affitech AS. R. A. Brekken is also an author of a patent on technology that was used to develop the antibody r84 by Peregrine Pharmaceuticals and Affitech AS. M. Nyquist-Andersen and A. Kavlie are employees of Affitech AS, and K. Schlunegger is an employee of Peregrine Pharmaceuticals, which supported these studies by providing r84, mcr84, and funding. Peregrine and Affitech did not participate in the planning, execution, or interpretation of the experiments. The authors affirm that they will adhere to the PLoS data sharing statement.
Author Contributions
Conceived and designed the experiments: LAS RAB. Performed the experiments: LAS JGC CLR JET. Analyzed the data: LAS CLR JR RAB. Contributed reagents/materials/analysis tools: LAS MNA AK KS. Wrote the paper: LAS RAB.